News

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. won the Second Prize in the Bio-medicine National Competition of the China Innovation & Entrepreneurship Grand Prix.

Published on:

2025-03-13 19:05

From November 19 to 21, 2024, the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix, organized by the Torch Center of the Ministry of Industry and Information Technology, was successfully concluded. During the event, numerous outstanding enterprises emerged in the bio-medicine field. Among them, EnliTISA (Shanghai) Pharmaceutical Co., Ltd. stood out with exceptional performance and was awarded the "Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix." ‌

Relevant news

2025-03-13

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. was recognized on the "Top 50 Innovation & Entrepreneurship Enterprises" list of the China Innovation & Entrepreneurship Competition.

EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was honored at the ‌Award Ceremony of the 13th China Innovation & Entrepreneurship Competition Finals‌ on December 7, 2024, organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology. The company was recognized on two prestigious lists: • ‌"Best Enterprise in Local Competitions of the 13th China Innovation & Entrepreneurship Competition"‌ • ‌"Top 50 Innovation & Entrepreneurship Enterprises of the 13th China Innovation & Entrepreneurship Competition"‌‌. The event highlighted outstanding enterprises from 37 regional competitions nationwide, with 1,000 companies advancing to the national stage‌. EnliTISA’s inclusion reflects its exemplary performance in technological innovation and industrial impact during the competition series.

2025-03-13

The company was honored with the ‌"2024 Pudong Innovation & Entrepreneurship Star"‌ award.

The 2024 Pudong Innovation & Entrepreneurship Conference, organized by the Shanghai Pudong New Area Economic and Science & Technology Commission, was officially inaugurated at the New Area People’s Government on November 29, 2024.

2025-03-13

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. was selected for the "2024 Shanghai Top 50 Most Investment-Promising Startups" list.

The 17th Bund Finance · Shanghai International Equity Investment Forum was held in Huangpu on December 10, 2024‌. With the theme "Invest in Shanghai, Innovate for the Future," the forum gathered top investors, industry experts, entrepreneurs, and innovators to explore collaborative opportunities‌. EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was selected for the "2024 Shanghai Top 50 Most Investment-Promising Startups" list announced at the event‌.

2025-03-13

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. won the Second Prize in the Bio-medicine National Competition of the China Innovation & Entrepreneurship Grand Prix.

From November 19 to 21, 2024, the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix, organized by the Torch Center of the Ministry of Industry and Information Technology, was successfully concluded. During the event, numerous outstanding enterprises emerged in the bio-medicine field. Among them, EnliTISA (Shanghai) Pharmaceutical Co., Ltd. stood out with exceptional performance and was awarded the "Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix."

2023-12-26

The first CTA and clinical study of EnliTISA Pharmaceuticals TISA-818 for treating idiopathic pulmonary fibrosis has been approved by the MPA

On November 27, 2023, EnliTISA Pharmaceuticals TISA-818, a Class I innovative drug for the treatment of idiopathic pulmonary fibrosis, was approved by the MPA.

2023-11-25

Completion of first patient first visit in phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome

The Phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome (ARDS) recently completed first patient first visit (FPFV), which was led by Professor Zhan Qingyuan of the China-Japan Friendship Hospital and sponsored by EnliTISA (Shang Hai) Pharmaceutical Co., Ltd (Abbreviated as EnliTISA).